Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
Technology appraisal guidance
Reference number: TA1086
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.